r/valueinvesting
ZTS - the more I dig, the more I go back and forth on it. Curious what this sub thinks.
Torn on ZTS: strong animal health moat and high margins vs. high leverage inflating ROE and sluggish 2.9% revenue growth.
- Strong moat in animal health due to vets' prescribing habits and lack of generic substitution, granting significant pricing power.
- Exceptionally high gross margins (71.84%) reflect its durable competitive position and pricing power.
- High leverage (D/E of 2.86x) artificially inflates ROE (67.75%), making the underlying return profile less impressive.
- Sluggish revenue growth (2.9% YoY) raises concerns about whether pricing power can accelerate and volume can recover.
Been looking at Zoetis for the past week and I keep landing in different places depending on which part of the analysis I'm staring at.
The moat case is real. Animal health doesn't work like human pharma vets don't price shop the way pharmacists do, in vet pharma, generic substitution just doesn't work the way it does in human healthcare - vets prescribe what they trust, pet owners don't ask for the cheaper version, and that pricing power holds, and the 71.84% gross margins reflect that. If you're thinking about it as a compounder you hold for a decade, the competitive position is genuinely durable.
Then I look at the balance sheet and my conviction drops. D/E at 2.86x is doing a lot of the work on that 67.75% ROE. Strip out the leverage and the return profile looks a lot less impressive. I keep asking whether I'm buying a great business or a leveraged version of a decent one, and I'm not sure I can answer that cleanly.
The other thing I can't shake: revenue growth at 2.9% YoY. The concentrated position thesis needs to believe that pricing power accelerates from here and volume picks up.
What's your read - moat strong enough to hold through the leverage, or does the balance sheet structure disqualify it from a high-quality portfolio?
The Company is fine. The Product is fine.
Management is the issue.
——
I wrote a long paragraph on why I sold it previously.
the leverage thing always trips people up with ZTS but the debt has basically been there since the pfizer spinoff..... roic in the high teens still looks solid even stripping out the leverage effect
the 2.9% growth number is the real tell for me..... librela headwinds plus pet spending softness and the stock already down 25% feels like the market priced some of that in already